Medexus Pharmaceuticals Inc (MDP) Price & Analysis

Compare

59 Followers

MDP Stock Chart & Stats

Day’s Range― - ―

52-Week RangeC$1.71 - C$5.56

Previous CloseN/A

Volume43.25K

Average Volume (3M)34.20K

Market Cap

C$101.61M

Enterprise ValueC$38.60M

Total Cash (Recent Filing)C$8.44M

Total Debt (Recent Filing)$39.91M

Price to Earnings (P/E)24.5

Beta1.09

Next Earnings

Aug 06, 2025

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.03

Shares Outstanding32,258,354

10 Day Avg. Volume54,153

30 Day Avg. Volume34,203

Financial Highlights & Ratios

PEG Ratio-0.14

Price to Book (P/B)1.05

Price to Sales (P/S)0.00

P/FCF Ratio-13.09

Enterprise Value/Market Cap0.38

Enterprise Value/Revenue0.09

Enterprise Value/Gross Profit0.67

Enterprise Value/Ebitda0.50

Forecast

1Y Price Target

C$7.00

Price Target Upside122.22% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering2

Medexus Pharmaceuticals Inc News

PremiumRatings

Positive Outlook for Medexus Pharmaceuticals: Buy Rating Affirmed by Analyst

15h ago

PremiumCompany Announcements

Medexus Pharmaceuticals’ Earnings Call Highlights GRAFAPEX Success

3d ago

PremiumCompany Announcements

Medexus Pharmaceuticals Reports Strong FY 2025 Results and Successful GRAFAPEX Launch

4d ago

PremiumPre-Earnings

MDP Upcoming Earnings Report: What to Expect?

7d ago

PremiumCompany Announcements

Medexus Pharmaceuticals Announces Fiscal Year 2025 Financial Results Conference Call

12d ago

PremiumCompany Announcements

Medexus Secures Public Reimbursement for Trecondyv® in Quebec

2M ago

PremiumCompany Announcements

Medexus Reports Strong Initial Uptake of GRAFAPEX™ in U.S. Market

3M ago

PremiumCompany Announcements

Medexus Returns Gleolan U.S. Rights to NX Development Corp.

4M ago

See All TSE:MDP News

See All News >

Bulls Say, Bears Say

Bulls Say

Financial PerformanceMedexus's FQ3 results were ahead of initial estimates, showing strong performance.

Product ApprovalU.S. FDA approves Treosulfan, marking a significant benefit to patients.

Bears Say

Generic RiskThere is generic risk in the base business with Rupall losing exclusivity.

Pricing ConcernsInitial pricing assumptions for GRAFAPEX appear optimistic.

Regulatory SetbackMedexus faces a negative Health Canada setback for Terbinafine.

Financials

Income Statement >

Options Prices

Currently, No data available

---

Ownership Overview

7.36% Insiders

0.45%

Mutual Funds

0.03% Other Institutional Investors

92.14% Public Companies and

Individual Investors

Detailed Ownership Overview >

MDP FAQ

What was Medexus Pharmaceuticals Inc’s price range in the past 12 months?

Medexus Pharmaceuticals Inc lowest stock price was C$1.71 and its highest was C$5.56 in the past 12 months.

What is Medexus Pharmaceuticals Inc’s market cap?

Medexus Pharmaceuticals Inc’s market cap is C$101.61M.

When is Medexus Pharmaceuticals Inc’s upcoming earnings report date?

Medexus Pharmaceuticals Inc’s upcoming earnings report date is Aug 06, 2025 which is in 38 days.

How were Medexus Pharmaceuticals Inc’s earnings last quarter?

Medexus Pharmaceuticals Inc released its earnings results on Jun 25, 2025. The company reported -C$0.027 earnings per share for the quarter, beating the consensus estimate of -C$0.086 by C$0.059.

Is Medexus Pharmaceuticals Inc overvalued?

According to Wall Street analysts Medexus Pharmaceuticals Inc’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Medexus Pharmaceuticals Inc pay dividends?

Medexus Pharmaceuticals Inc does not currently pay dividends.

What is Medexus Pharmaceuticals Inc’s EPS estimate?

Medexus Pharmaceuticals Inc’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Medexus Pharmaceuticals Inc have?

Medexus Pharmaceuticals Inc has 32,258,354 shares outstanding.

What happened to Medexus Pharmaceuticals Inc’s price movement after its last earnings report?

Medexus Pharmaceuticals Inc reported an EPS of -C$0.027 in its last earnings report, beating expectations of -C$0.086. Following the earnings report the stock price went down -5.97%.

Which hedge fund is a major shareholder of Medexus Pharmaceuticals Inc?

Currently, no hedge funds are holding shares in TSE:MDP

Medexus Pharmaceuticals Inc Stock Smart Score

Neutral

Fundamentals

Return on Equity

5.27%

Trailing 12-Months

Asset Growth

17.35%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Medexus Pharmaceuticals Inc

Medexus Pharmaceuticals Inc. (MDP) is a specialty pharmaceutical company operating primarily in North America. The company focuses on the acquisition, licensing, and distribution of innovative and high-value medications across various therapeutic areas including autoimmune diseases, hematology, and allergies. Medexus aims to address unmet medical needs by delivering products that improve patient outcomes and quality of life.

MDP Stock 12 Month Forecast

Average Price Target

C$7.00

▲(122.22%Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"C$0","9":"C$9","2.25":"C$2.25","4.5":"C$4.5","6.75":"C$6.75"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":8,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">C$8.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":7,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">C$7.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":6,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">C$6.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[0,2.25,4.5,6.75,9],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jun<br/>2024","6":"Sep<br/>2024","9":"Jan<br/>2025","12":"Jun<br/>2025","25":"Jun<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.93,3.3200000000000003,3.71,4.1,4.49,4.880000000000001,5.27,5.66,6.050000000000001,6.44,6.83,7.220000000000001,7.609999999999999,{"y":8,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.93,3.243076923076923,3.556153846153846,3.8692307692307697,4.182307692307693,4.495384615384616,4.808461538461539,5.121538461538462,5.434615384615385,5.747692307692308,6.060769230769231,6.373846153846154,6.686923076923078,{"y":7,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.93,3.166153846153846,3.4023076923076925,3.6384615384615384,3.874615384615385,4.110769230769231,4.346923076923077,4.5830769230769235,4.819230769230769,5.055384615384615,5.291538461538462,5.527692307692307,5.763846153846154,{"y":6,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":1.45,"date":1701388800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.34,"date":1706745600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.82,"date":1709251200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.62,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.82,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.35,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.45,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.43,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.82,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.46,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.85,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.49,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.93,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >